These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 19715915

  • 1. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function.
    Fernández A, Marcén R, Galeano C, Caldés S, Amezquita Y, Villafruela J, Pascual J, Burgos J, Rodríguez-Mendiola N, Ortuño J.
    Transplant Proc; 2009; 41(6):2345-7. PubMed ID: 19715915
    [Abstract] [Full Text] [Related]

  • 2. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 4. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 5. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 6. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, Klinger M.
    Transplant Proc; 2006 Dec; 38(1):101-4. PubMed ID: 16504675
    [Abstract] [Full Text] [Related]

  • 7. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO.
    Transplant Proc; 2009 Dec; 41(6):2659-63. PubMed ID: 19715995
    [Abstract] [Full Text] [Related]

  • 8. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
    Fernández A, Marcén R, Pascual J, Galeano C, Ocaña J, Arellano EM, Alfaro C, Villafruela JJ, Burgos FJ, Ortuño J.
    Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
    [Abstract] [Full Text] [Related]

  • 9. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G, Pisani F, Iorio B, Lucchesi C, De Luca L, Ielpo B, D'Andria D, Tariciotti L, Tisone G.
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [Abstract] [Full Text] [Related]

  • 10. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
    Gutiérrez MJ, González E, Andrés A, Morales JM.
    Transplant Proc; 2009 May; 41(6):2348-50. PubMed ID: 19715916
    [Abstract] [Full Text] [Related]

  • 11. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine.
    Gonzalez Molina M, Morales JM, Marcen R, Campistol JM, Oppenheimer F, Serón D, Gil-Vernet S, Capdevila L, Andrés A, Lampreave I, Del Castillo D, Cabello M, Burgos D, Valdés F, Anaya F, Escuín F, Arias M, Pallardó L, Bustamante J.
    Transplant Proc; 2007 Sep; 39(7):2167-9. PubMed ID: 17889126
    [Abstract] [Full Text] [Related]

  • 12. Conversion to everolimus in kidney transplant recipients with decreased renal function.
    Inza A, Balda S, Alvarez E, Zárraga S, Gaínza FJ, Lampreabe I.
    Transplant Proc; 2009 Sep; 41(6):2134-6. PubMed ID: 19715854
    [Abstract] [Full Text] [Related]

  • 13. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
    Ruiz JC, Campistol JM, Sánchez-Fructuoso A, Rivera C, Oliver J, Ramos D, Campos B, Arias M, Diekmann F.
    Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
    [Abstract] [Full Text] [Related]

  • 14. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients.
    Laham G, Sleiman S, Soler Pujol G, Diaz C, Dávalos M, Vilches A.
    Transplant Proc; 2010 Nov; 42(1):309-13. PubMed ID: 20172338
    [Abstract] [Full Text] [Related]

  • 15. Late conversion to everolimus complicated with necrotizing glomerulonephritis in a renal allograft recipient: case report.
    Nowacka-Cieciura E, Perkowska-Ptasińska A, Sulikowska-Rowińska A, Cieciura T, Wazna E, Durlik M.
    Transplant Proc; 2009 Nov; 41(1):441-5. PubMed ID: 19249576
    [Abstract] [Full Text] [Related]

  • 16. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [Abstract] [Full Text] [Related]

  • 17. Optimization of immunosuppression by switching from azathioprine to enteric-coated mycophenolate sodium in stable kidney transplant patients.
    Gutiérrez Sánchez MJ, Morales Cerdán JM, Belmonte AA.
    Transplant Proc; 2009 Jun; 41(6):2320-2. PubMed ID: 19715907
    [Abstract] [Full Text] [Related]

  • 18. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM, Sahin S, Kantarci G, Ergin H.
    Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
    [Abstract] [Full Text] [Related]

  • 19. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation.
    Falkiewicz K, Kamińska D, Nahaczewska W, Boratyńska M, Owczarek H, Klinger M, Woźniak M, Patrzałek D, Szyber P.
    Transplant Proc; 2006 Dec; 38(1):119-22. PubMed ID: 16504680
    [Abstract] [Full Text] [Related]

  • 20. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM, Andrés A, Dominguez-Gil B, Arriola M, Gutiérrez MJ, Hernández E, Ortuño T, Praga M.
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.